Peptides for Focus and Brain Fog: What Works and What the Research Says

Key Takeaways

• Compounds covered: Semax, selank, BPC-157
• Goal area: Focus, attention, cognitive clarity, brain fog reduction
• Evidence range: Ranges from limited human neuroimaging and stroke recovery data (semax, selank) to animal-only data (BPC-157 for CNS effects)
• Key biomarkers for focus and brain fog: TSH, vitamin B12, hs-CRP, fasting glucose, HbA1c, comprehensive metabolic panel
• Regulatory status (as of publication, April 2026): None of the compounds profiled is FDA-approved for focus or brain fog. All three (semax, selank, BPC-157) are classified by FDA as §503A Category 2 bulk drug substances; compounding from bulk is not covered by FDA's enforcement discretion. As of April 22, 2026, semax remains on FDA's §503A Category 2 interim list; compounding from bulk semax is not covered by FDA's enforcement discretion, and there is no FDA-sanctioned US compounding pathway for semax. None is available through Superpower.
• Bottom line: Reversible contributors to brain fog — thyroid dysfunction, B12 deficiency, insulin resistance, chronic inflammation — should be evaluated and addressed before any investigational neuropeptide is considered.

Understanding Focus and Brain Fog: The Biology

Focus is a cognitive capacity rooted in prefrontal cortex function. The prefrontal cortex coordinates working memory, sustained attention, and executive control — the ability to maintain a goal-relevant thought stream while filtering distracting inputs. This region is acutely sensitive to neurotransmitter availability, particularly dopamine. Dopaminergic tone in the prefrontal cortex is often described as following an inverted-U dose-response curve, in which too little reduces cognitive control and excess can also impair it. The implication is that interventions targeting dopaminergic pathways have a narrow effective window that differs substantially across individuals.

Brain fog is not a clinical diagnosis. It is a symptom cluster that typically describes cognitive slowing, difficulty with word retrieval, impaired concentration, and mental fatigue. The underlying mechanisms are heterogeneous. Hypothyroidism suppresses cerebral metabolism and produces nearly identical symptoms. Vitamin B12 deficiency impairs myelin synthesis and neuronal conduction. Insulin resistance reduces cerebral glucose utilization, effectively starving the prefrontal cortex of its primary fuel. Chronic systemic inflammation — elevated hs-CRP — has been associated in epidemiological studies with cognitive slowing and has been proposed to contribute via cytokine-mediated pathways affecting hippocampal function.

A separate mechanism relevant to brain fog is the gut-brain axis. The intestinal epithelium and the central nervous system are connected through the vagus nerve, the enteric nervous system (over 500 million neurons in the gut wall), and circulating neuroactive metabolites produced by gut microbiota. Disruption of intestinal barrier integrity has been proposed to allow microbial-derived lipopolysaccharides to enter systemic circulation and to contribute to low-grade neuroinflammation. This pathway is the mechanistic basis for interest in gut-targeted peptides as potential contributors to cognitive clarity.

Neuropeptides have been proposed to interact with these systems through several mechanisms: BDNF-trkB upregulation (implicated in synaptic maintenance and memory consolidation), dopaminergic and serotonergic modulation (implicated in prefrontal attentional networks), GABAergic tone (implicated in anxiety-driven prefrontal inhibition), and gut cytoprotection (implicated in intestinal barrier function upstream of neuroinflammation).

Peptides Studied for Focus and Brain Fog: A Quick Comparison

The following peptides have published evidence relevant to focus, attention, or brain fog. They are listed by strength of available clinical evidence, from most-studied to least.

• Compound: Semax
  Mechanism for focus: ACTH(4-10) analog; upregulates BDNF-trkB in hippocampus; activates dopaminergic and serotonergic prefrontal systems
  Evidence: Limited human studies including stroke recovery with BDNF elevation and neuroimaging in healthy subjects; no Phase 2 or Phase 3 RCT for focus in healthy adults
  FDA status: Not FDA-approved; classified by FDA as a §503A Category 2 bulk drug substance — compounding from bulk not covered by FDA's enforcement discretion; as of April 22, 2026, remains on FDA's §503A Category 2 interim list
  Route: Intranasal spray
• Compound: Selank
  Mechanism for focus: Tuftsin analog; GABAergic modulation and BDNF upregulation; anxiolytic effects may support prefrontal function under stress
  Evidence: Limited human data including neuroimaging and anxiolytic clinical studies; no Phase 2 or Phase 3 RCT for healthy-adult focus enhancement
  FDA status: Not FDA-approved; classified by FDA as a §503A Category 2 bulk drug substance — compounding from bulk not covered by FDA's enforcement discretion
  Route: Intranasal spray
• Compound: BPC-157
  Mechanism for brain fog: Gut cytoprotection and intestinal barrier support; gut-brain axis modulation through vagal and serotonergic pathways
  Evidence: Animal studies only for CNS effects; no completed human clinical trials for focus or brain fog
  FDA status: Not FDA-approved; classified by FDA as a §503A Category 2 bulk drug substance — compounding from bulk not covered by FDA's enforcement discretion
  Route: Oral (gavage) and subcutaneous routes used in animal studies; human route for CNS effects has not been established in clinical trials

BPC-157 is listed as a research-only compound for CNS applications. It has not completed the clinical trial process required for FDA approval. BPC-157 is classified by FDA as a §503A Category 2 bulk drug substance; compounding from bulk BPC-157 is not covered by FDA's enforcement discretion under §503A. Inclusion here is for educational context only.

Peptides Studied for Focus and Brain Fog: Individual Profiles

Each compound targets a distinct mechanism and has been studied using distinct methods. Cross-compound comparisons require an explicit caveat: these compounds have been studied in different populations, at different doses, and with different endpoints. Inferring relative effectiveness across separate preclinical or limited human studies is not methodologically valid.

Semax

Semax is a synthetic heptapeptide analog of the ACTH(4-10) sequence. For focus and cognitive function, its proposed mechanism centers on neurotrophic signaling: Dolotov and colleagues published evidence in Brain Research in 2006 that semax regulates BDNF/trkB in hippocampus following intranasal delivery — the primary mechanistic basis for research on cognitive-related effects. Eremin and colleagues, in a 2004 Doklady Biological Sciences study, characterized dopaminergic and serotonergic brain effects. The monoaminergic mechanism is equally relevant to focus: Dolotov and colleagues published evidence in Neurochemical Research in 2005 that semax activates dopaminergic and serotonergic systems in rodents.

The most clinically relevant human data comes from stroke recovery. A 2018 study by Gusev and colleagues published in Zhurnal Nevrologii i Psikhiatrii documented clinical efficacy in ischemic stroke, including BDNF elevation and cognitive improvement. An earlier study by Gusev and colleagues from 1997 reported electrophysiological improvement in ischemic stroke following semax treatment. A supporting neuroprotection citation comes from Skvortsova and colleagues, whose 1999 publication in the same journal investigated neuroprotective mechanisms in ischemic stroke. Neuroimaging evidence from Panikratova and colleagues in Doklady Biological Sciences in 2020 documented semax's effects on resting-state brain networks in healthy subjects — the best available evidence for functional brain effects in a non-diseased population. Manchenko and colleagues, publishing in Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova in 2010, reported nootropic and analgesic effects in rats in a preclinical rat model (not a healthy-adult focus enhancement trial).

[Limited human neuroimaging and stroke-population data; no Phase 2 or Phase 3 RCT for healthy-adult focus enhancement] Semax is not FDA-approved for any indication in the United States. FDA placed semax on the §503A Category 2 bulk drug substances list, meaning compounding from bulk semax is not covered by FDA's enforcement discretion. As of April 22, 2026, semax remains on FDA's §503A Category 2 interim list. There is no FDA-sanctioned US compounding pathway for semax for focus or cognitive enhancement. Not available through Superpower.

Selank

Selank is a synthetic tuftsin analog with a proposed mechanism relevant to focus through anxiety reduction. Anxiety disrupts prefrontal cognitive control by activating threat-detection circuits that compete with goal-directed attentional networks — reducing GABAergic inhibitory tone is one mechanism by which this disruption can be addressed. Filatova and colleagues, in Frontiers in Pharmacology in 2017, showed that selank affects genes involved in GABAergic neurotransmission, and a 2016 paper by Volkova and colleagues in Frontiers in Pharmacology confirmed selank's regulation of GABAergic gene expression. Zozulia and colleagues, writing in Zhurnal Nevrologii i Psikhiatrii in 2008, reported selank's efficacy and mechanisms as anxiolytic. Kasian and colleagues, in Behavioural Neurology in 2017, also showed that selank enhances diazepam effect under stress, indicating functional synergy with GABAergic signaling.

The BDNF pathway is also relevant: Kolik and colleagues published evidence in Bulletin of Experimental Biology and Medicine in 2019 that selank protects against ethanol-induced memory impairment in the hippocampus and prefrontal cortex — connecting selank's mechanism directly to memory-relevant brain regions. The neuroimaging study by Panikratova and colleagues in Doklady Biological Sciences in 2020 documented both semax and selank's effects on resting-state networks in healthy subjects. A preclinical study by Slominsky and colleagues published in Doklady Biological Sciences in 2017 examined in a Parkinson's-like model; the authors reported neuroprotective signals in that preclinical setting.

[Limited human data including neuroimaging; no Phase 2 or Phase 3 RCT for healthy-adult focus enhancement] Selank is not FDA-approved for any indication in the United States. FDA placed selank on the §503A Category 2 bulk drug substances list; compounding from bulk selank is not covered by FDA's enforcement discretion. There is no FDA-sanctioned US compounding pathway for selank for focus, anxiety, or cognitive enhancement. Not available through Superpower.

BPC-157

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protein found in human gastric juice, developed by Sikiric and colleagues at the University of Zagreb and studied primarily for its gastrointestinal cytoprotective properties. Its relevance to brain fog rests on the gut-brain axis mechanism: Sikiric and colleagues published a key review in Current Neuropharmacology in 2016 establishing proposed brain-gut axis activity, proposing that its gut-protective effects extend upward through the vagal-enteric system to CNS function. A 2023 paper by Sikiric and colleagues in Pharmaceuticals argued that BPC-157 may support brain-gut axis function in preclinical models of disruption.

BPC-157 also has proposed direct CNS effects. Sikiric and colleagues published a comprehensive CNS review in Neural Regeneration Research in 2022 documenting BPC-157's central nervous system effects across multiple neurotransmitter systems. A 2024 paper by Sikiric and colleagues in Pharmaceuticals reviewed BPC-157's pleiotropic activity. Tohyama and colleagues, writing in Life Sciences in 2004, demonstrated region-specific influence on brain serotonin — a mechanism connecting gut-targeted activity to central serotonergic function. Sikirić and colleagues, publishing in Digestive Diseases and Sciences in 1997, documented interactions with adrenergic and dopaminergic systems under stress conditions. A comprehensive review by Jozwiak and colleagues published in Pharmaceuticals in 2025 summarized BPC-157 multifunctionality across its studied applications. Sikiric and colleagues' 2017 review in Current Pharmaceutical Design contextualized how GI stress disrupts brain function and BPC-157's potential role in that system. [Animal studies only for CNS and cognitive effects — no completed human clinical trials]

This compound has not been approved by the FDA for any medical use. As of April 2026, BPC-157 is classified by FDA as a §503A Category 2 bulk drug substance; compounding from bulk is not covered by FDA's enforcement discretion under §503A. BPC-157 is not prescribed, compounded, or dispensed through Superpower. Inclusion is for educational context only.

Regulatory Status at a Glance

As of April 2026, the peptides discussed in this article carry different regulatory statuses. These distinctions matter when discussing any of them with a healthcare provider.

• Semax: Not FDA-approved for any indication. Classified by FDA as a §503A Category 2 bulk drug substance; compounding from bulk semax is not covered by FDA's enforcement discretion. As of April 22, 2026, semax remains on FDA's §503A Category 2 interim list. No US FDA NDA or BLA has been submitted or approved for semax; Russian regulatory approval has no legal effect on US market access, and no US FDA review has evaluated semax's safety or efficacy for any indication.
• Selank: Not FDA-approved for any indication. Classified by FDA as a §503A Category 2 bulk drug substance; compounding from bulk selank is not covered by FDA's enforcement discretion. No US FDA NDA or BLA has been submitted or approved for selank; Russian regulatory approval has no legal effect on US market access.
• BPC-157: Not FDA-approved for any indication. Classified by FDA as a §503A Category 2 bulk drug substance as of April 2026; compounding from bulk is not covered by FDA's enforcement discretion under §503A. BPC-157 is not on the FDA 503A bulks list, has no USP-NF monograph, and is not a component of any FDA-approved drug.

Vanhee and colleagues, writing in Drug Testing and Analysis in 2020, documented cognitive peptides in seized preparations without licensed oversight — illustrating the sourcing risks in the unregulated market. Mendias and colleagues, reviewing the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance in Sports Medicine in 2026, noted that safety and efficacy of unapproved peptide therapies remain insufficiently established in the musculoskeletal/athletic domain — a scoping caveat that generalizes to cognitive peptide use where even less controlled-trial data exists.

Considerations When Comparing Peptides for Focus and Brain Fog

Direct comparison between semax, selank, and BPC-157 for focus or brain fog is not methodologically supported — they have been studied in different animal models, at different doses, and with different cognitive endpoints. A licensed provider evaluating someone with cognitive complaints would first determine whether the symptoms have an identifiable and addressable cause before any peptide discussion could proceed.

Your specific cognitive symptom profile: Anxiety-driven attentional disruption, where worry and stress impair prefrontal function, differs mechanistically from the cognitive slowing associated with neuroinflammation or gut-brain axis disruption. Selank's anxiolytic profile and BPC-157's gut-targeted mechanism represent different starting points for different symptom presentations.

Existing health conditions and biomarker profile: Hypothyroidism, vitamin B12 deficiency, insulin resistance, and elevated systemic inflammation are among the most common reversible contributors to brain fog. A provider will typically address these before considering investigational peptides. Testing TSH and vitamin B12 as a first step is clinically standard.

Evidence level and regulatory status: Semax and selank have at least limited human data (from Russian clinical settings, not evaluated by the FDA). BPC-157 has no human cognitive data. All three compounds are on FDA's §503A Category 2 bulk drug substances list, meaning compounding from bulk is not covered by FDA's enforcement discretion. None of the three has an FDA-sanctioned US compounding pathway for focus or brain fog.

Route and protocol: Semax and selank are intranasal — a route that requires consistent technique for reliable dosing. BPC-157 has been studied orally and subcutaneously in animal models; human route for CNS effects is not established from clinical data.

This is not an exhaustive list of clinical considerations. A licensed provider will evaluate your full health history, current medications, and baseline lab results before recommending any compound.

Safety Considerations

Safety data for all three compounds is limited relative to FDA-reviewed medications. Semax and selank have some human safety reporting from Russian clinical experience, which is not evaluated by the FDA and should not be considered equivalent to US regulatory safety data; BPC-157 has no published human safety data for CNS applications.

Contraindications that apply broadly to this compound class include:

• Pregnancy and breastfeeding — no reproductive safety data exists for any compound in this category
• Active CNS or GI malignancy — compounds with growth factor pathway activity carry theoretical proliferative concerns not specifically studied in these populations
• Concurrent GABAergic medications — selank's documented synergy with diazepam raises an interaction consideration for anyone on benzodiazepines or other GABA modulators
• Unregulated sourcing — the Vanhee 2020 survey documented contamination and misidentification in gray-market cognitive peptide preparations; products purchased outside licensed pharmacy channels carry risks that cannot be mitigated by the end user

For compound-specific safety profiles, see individual compound pages as the peptides cluster expands.

What to Test Before Starting Peptides for Focus

Regardless of which compound you and your provider discuss, baseline biomarker testing is the first step — and for brain fog specifically, it is often the only step needed. The majority of brain fog presentations in otherwise healthy adults have identifiable metabolic or nutritional contributors that respond to targeted interventions more predictably than investigational peptides.

• TSH (thyroid-stimulating hormone): Measures the pituitary's thyroid-stimulating signal. Why it matters: hypothyroidism is among the most common reversible causes of cognitive slowing, memory impairment, and brain fog. TSH testing should precede any cognitive intervention in a clinical evaluation. The thyroid biomarker testing guide at Superpower provides context for interpreting thyroid function results.
• Vitamin B12: Measures circulating B12, essential for myelin synthesis. Why it matters for focus: deficiency causes measurable slowing of neural conduction and progressive cognitive impairment, fully reversible with correction. Vitamin B12 testing is especially relevant for adults over 50, vegetarians, and those on proton pump inhibitors.
• hs-CRP: A sensitive systemic inflammation marker. Why it matters: neuroinflammation is a documented contributor to cognitive slowing, and elevated systemic CRP is associated with worse cognitive trajectories. High-sensitivity CRP provides the inflammatory baseline that contextualizes any gut-targeted or anti-inflammatory intervention.
• Fasting glucose: Measures current blood glucose. Why it matters: insulin resistance impairs cerebral glucose utilization — the primary fuel for prefrontal function. Fasting glucose testing establishes whether metabolic dysregulation is contributing to cognitive symptoms.
• HbA1c: The 3-month average of blood glucose. Why it matters: chronic hyperglycemia is associated with impaired hippocampal neurogenesis and long-term cognitive decline. HbA1c testing complements fasting glucose by capturing the 90-day glycemic context.
• IGF-1: The primary downstream marker of growth hormone axis activity. Why it matters for cognitive health: IGF-1 supports hippocampal neurogenesis and synaptic maintenance. IGF-1 levels provide context for neurotrophic factor availability at baseline.
• Comprehensive metabolic panel (ALT, AST, eGFR): Liver and kidney function markers that establish safety context for any compound with hepatic or renal processing requirements.

TSH, vitamin B12, hs-CRP, fasting glucose, and HbA1c together address the most common reversible contributors to brain fog before any peptide compound enters the discussion. Testing mental clarity and focus biomarkers at baseline creates the objective reference that makes subsequent evaluation meaningful.

How to Access These Peptides Safely

Semax, selank, and BPC-157 are all classified by FDA as §503A Category 2 bulk drug substances as of April 2026. As of April 22, 2026, semax remains on FDA's §503A Category 2 interim list. This means compounding any of these substances from bulk is not covered by FDA's enforcement discretion under §503A. There is no FDA-sanctioned US compounding pathway for any of the three compounds for focus or brain fog indications, and no FDA-approved product exists.

Products sold online as semax, selank, or BPC-157 operate outside pharmaceutical manufacturing oversight. Vanhee and colleagues (2020) documented cognitive-enhancing research peptides including semax and selank in seized preparations without licensed oversight, illustrating the contamination and misidentification risks of the unregulated market. Sourcing any injectable or intranasal peptide outside licensed pharmacy channels is not a safe substitute for a provider-supervised protocol.

The experience that drives a search for focus-enhancing peptides often reflects a genuine cognitive concern worth taking seriously. That concern deserves a clinical evaluation — bloodwork first, compound discussion second.

Understanding Your Baseline

With three compounds profiled — each targeting a different mechanism and carrying a different regulatory status — the question of which is relevant to a specific cognitive complaint cannot be answered without objective data about that individual's biology. A TSH in the subclinical hypothyroid range, a vitamin B12 at the lower limit of the reference range, or an hs-CRP above 3 mg/L each points toward an intervention with a much stronger evidence base than any investigational neuropeptide. Baseline testing makes those distinctions visible.

That principle is central to Superpower's approach to preventive health. Whether the conversation with your provider leads to addressing a reversible metabolic contributor, discussing a compounded neuropeptide, or pursuing a different path, the starting point is the same: knowing where your biomarkers stand.

IMPORTANT SAFETY INFORMATION

Semax is not approved by the FDA for any indication. FDA placed semax on the §503A Category 2 bulk drug substances list, meaning compounding from bulk semax is not covered by FDA's enforcement discretion. There is no FDA-sanctioned US compounding pathway for semax for focus, cognitive enhancement, or any other indication. As of April 22, 2026, semax remains on FDA's §503A Category 2 interim list. Safety and efficacy for any use have not been established through adequate and well-controlled clinical trials under FDA standards. Superpower does not currently offer semax. Consult a licensed healthcare provider before initiating any peptide therapy. Potential interaction with GABAergic medications should be discussed with a provider. Effects reported in Russian clinical experience (not evaluated by the FDA) include mild headache and transient nasal irritation with intranasal administration; systematic adverse event data meeting FDA standards does not exist for healthy-population cognitive use.

Selank is not approved by the FDA for any indication. FDA placed selank on the §503A Category 2 bulk drug substances list, meaning compounding from bulk selank is not covered by FDA's enforcement discretion. There is no FDA-sanctioned US compounding pathway for selank for focus, cognitive enhancement, anxiety, or any other indication. Safety and efficacy for any use have not been established through adequate and well-controlled clinical trials under FDA standards. Superpower does not currently offer selank. Synergistic interaction with benzodiazepines has been documented in preclinical studies; consult a provider before use alongside GABAergic medications.

BPC-157 is not approved by the FDA for any medical use. As of April 2026, BPC-157 is classified by FDA as a §503A Category 2 bulk drug substance; compounding from bulk is not covered by FDA's enforcement discretion under §503A. Research on BPC-157 for CNS or cognitive applications has been limited to animal studies, with no completed human clinical trial data available. Its safety, efficacy, appropriate dosing, and long-term effects in humans for these indications have not been established. BPC-157 is not prescribed, compounded, or dispensed through Superpower. This section is provided for educational purposes only and does not constitute medical advice or an endorsement of use.

Full FDA-approved prescribing information for any prescription compound at dailymed.nlm.nih.gov.